Baker Bros. Advisors’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Baker Bros. Advisors’s Portfolio CNST Stock Details CNST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-114,735	Closed	-$2.68M	–	135
2021 Q1	$2.68M	Hold	114,735	–	–	0.01%	109
2020 Q4	$3.3M	Sell	114,735 -18,598	-14%	-$468K	0.01%	101
2020 Q3	$2.7M	Hold	133,333	–	–	0.01%	96
2020 Q2	$4.01M	Hold	133,333	–	–	0.02%	84
2020 Q1	$4.19M	Hold	133,333	–	–	0.03%	69
2019 Q4	$6.28M	Hold	133,333	–	–	0.03%	64
2019 Q3	$861K	Hold	133,333	–	–	0.01%	100
2019 Q2	$1.64M	Hold	133,333	–	–	0.01%	88
2019 Q1	$1.81M	Hold	133,333	–	–	0.01%	83
2018 Q4	$535K	Hold	133,333	–	–	﹤0.01%	90
2018 Q3	$897K	Buy	+133,333	New	+$1.27M	0.01%	93

Other funds holding CNST

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

OPU

Omni Partners US Irvine, California $1.95B AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

PIM

Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baker Bros. Advisors's CNST Position: Q2 2021 in Review

Baker Bros. Advisors sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q2 2021, closing a stake of 114,735 shares — an estimated $2.68M sold.

Baker Bros. Advisors first reported a position in CNST in Q3 2018 and held it in 11 quarters. The position peaked at $6.28M in Q4 2019. 153 funds tracked by Wall St. Rank hold CNST as of Q2 2021.

Baker Bros. Advisors reported no remaining Constellation Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
Baker Bros. Advisors sold 114,735 Constellation Pharmaceuticals, Inc. shares in Q2 2021, an estimated $2.68M.
Baker Bros. Advisors first reported a position in Constellation Pharmaceuticals, Inc. in Q3 2018 and held it in 11 quarters.
Baker Bros. Advisors's Constellation Pharmaceuticals, Inc. position peaked at $6.28M in Q4 2019.
153 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q2 2021.

Based on Baker Bros. Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.